	US 11,931,401 B2
	Runx3 modified protein for prevention or treatment of cancer
Suk Chul Bae, Cheongju-si (KR); Jung Won Lee, Daejeon (KR); and You Soub Lee, Cheongju-si (KR)
Assigned to GeneCraft Inc., Cheongju-si (KR)
Filed by GeneCraft Inc., Cheongju-si (KR)
Filed on Apr. 23, 2021, as Appl. No. 17/239,289.
Claims priority of application No. 10-2020-0049341 (KR), filed on Apr. 23, 2020; and application No. 10-2020-0184526 (KR), filed on Dec. 28, 2020.
Prior Publication US 2021/0330740 A1, Oct. 28, 2021
Int. Cl. A61K 38/17 (2006.01); A61K 31/436 (2006.01); A61K 31/519 (2006.01); A61K 47/46 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C12N 7/00 (2006.01)

CPC A61K 38/17 (2013.01) [A61K 31/436 (2013.01); A61K 31/519 (2013.01); A61K 38/1709 (2013.01); A61K 47/46 (2013.01); A61P 35/00 (2018.01); C07K 14/4702 (2013.01); C12N 7/00 (2013.01); C12N 2750/14143 (2013.01)]

11 Claims

1. A method for treating cancer comprising administering a modified protein, a polynucleotide encoding the modified protein, a vector carrying the polynucleotide, or a virus or cell transformed with the vector, in a pharmaceutically effective amount to a subject in need thereof,

wherein the modified protein is a Runx3 (Runt-related transcription factor 3) protein in which the 356^thserine according to SEQ ID NO: 2 is substituted with an amino acid that cannot be phosphorylated by a kinase, and wherein the cancer is lung, stomach, or pancreatic cancer.